Hexahydrocurcumin 是一种选择性口服活性COX-2抑制剂，对 COX-1 无活性，是姜黄素的主要代谢产物之一，。它具有抗氧化，抗癌和抗炎作用。

Hexahydrocurcumin is a selective, orally active COX-2 inhibitor and inactive against COX-1.

Hexahydrocurcumin (0-25 μM; 24-48 hours; HT-29 cells) treatment significantly decreased the viability of HT-29 colon cancer cells in a time- and concentration-dependent. The respective IC50 values for 24 and 48 h of Hexahydrocurcumin exposure are 77.05 and 56.95, respectively. Hexahydrocurcumin (0-25 μM; 24-48 hours; HT-29 cells) combined with 5-fluorouracil (5-FU; 5 μM) markedly reduces the COX-2 expression. The level of COX-1 is not altered [1]. Hexahydrocurcumin (7-14 μM; 24 hours) attenuates LPS-elicited increase of prostaglandin E2 (PGE2) in murine macrophages (RAW 264.7) in a concentration-dependent manner [2].

In colon cancer rats, Hexahydrocurcumin (50 mg/kg; oral administration; daily; for 16 weeks; male Wistar rats) treatment significantly reduces the numbers of aberrant crypt foci. Hexahydrocurcumin also markedly decreases COX-2 protein expression [3].

Cell Line: HT-29 cells. Concentration: 0 μM, 5 μM, 10 μM, 25 μM. Incubation Time: 24 hours or 48 hours [1]

Animal Model: Male Wistar rats (100-120 g) injected with dimethylhydrazine (DMH). Dosage: 50 mg/kg. Administration: Oral administration; daily; for 16 weeks [3]

36062-05-2

C21H26O6

374.43

DMSO:45 mg/mL (120.19 mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years